Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

In this podcast, Helena Yu, MD, discusses recent advances in the field of antibody–drug conjugates and the current rationale for targeting HER3 for treatment of non-small-cell lung cancer.